INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*	ATTY. DOCKET NO. PC23170A	SERIAL NO. 10/596,504
	APPLICANT Hua Zhu Ke	
	FILING DATE	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	2	8	3	4	7	1	2	5-13-58	Beall, et al			
	US	3	8	2	2	2	8	7	7-2-74	Bolger, et al	260	326.5	
	US	3	9	1	6	8	9	9	11-4-75	Theeuwes, et al	128	260	
	US	3	9	7	7	4	0	4	8-31-76	Theeuwes	128	260	
	US	4	4	1	8	0	6	8	11-29-83	Jones, et al	424	267	
	US	4	6	2	3	6	6	0	11-18-86	Richardson	514	514	
	US	4	6	9	6	9	4	9	9-29-87	Toivola, et al	514	648	
	US	4	7	9	2	4	4	8	12-20-88	Ranade	424	438	
	US	4	8	3	9	1	5	5	6-13-89	McCague	424	1.1	
	US	4	9	9	6	2	2	5	2-26-91	Toivola, et al	514	428	
	US	5	0	4	7	4	9	1	9-10-91	Schickaneder, et al	514	648	
	US	5	3	9	3	7	6	3	2-28-95	Black, et al	514	333	
	US	5	4	5	5	0	4	6	10-3-95	Baichwal, et al	424	457	
	US	5	4	5	7	1	1	7	10-10-95	Black, et al	514	337	
	US	5	4	6	4	8	4	5	11-7-95	Black, et al	514	326	
	US	5	4	7	8	8	4	7	12-26-95	Draper	514	333	
	US	5	4	8	4	7	9	5	1-16-96	Bryant, et al	514	319	
	US	5	5	1	2	2	9	7	4-30-96	Baichwal	424	451	
	US	5	5	5	2	4	1	2	9-3-96	Cameron, et al	514	317	
	US	5	6	1	2	0	5	9	3-18-97	Cardinal, et al	424	495	
	US	5	6	4	1	7	9	0	6-24-97	Draper	514	333	
	US	5	6	9	8	2	2	0	12-16-97	Cardinal, et al	424	451	
	US	5	7	8	0	4	9	7	7-14-98	Miller, et al	514	414	
	US	5	8	2	7	5	3	8	10-27-98	Cussler, et al	424	473	
	US	5	8	8	0	1	3	7	9-9-99	Miller, et al	514	323	
	US	5	9	8	5	9	1	0	11-16-99	Miller, et al	514	415	
	US	5	9	9	8	4	0	2	12-7-99	Miller, et al	514	212	

INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*	ATTY. DOCKET NO. PC23170A	SERIAL NO. 10/596,504
	APPLICANT Hua Zhu Ke	
	FILING DATE	GROUP

	US	6	2	0	4	2	8	6	3-20-01	Cameron, et al	514	428	
	US	6	5	5	2	0	6	7	4-22-03	Cameron, et al	514	424	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	EP	0	3	7	8	4	0	4	1-10-90	European	A61M	31/00		
	EP	0	6	0	5	1	9	3	12-22-93	European	A61K	31/40		
	EP	0	8	0	2	1	8	3	4-15-97	European	C07D	209/10		
	WO	9	5	1	0	5	1	3	4-20-95	International	C07D	333/56		

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

			US Patent Application Publication No. US 2002/00004495, Pub. Date: 1-10-02, Harada, et al; US. Class 514/81
			US Patent Application Publication No. US 2002/0065308, Pub. Date: 5-30-02, Cameron, et al; US. Class 514/381
			US Patent Application Publication No. US 2003/0149086, Pub. Date: 8-17-03, Cameron, et al; US. Class 514/365
			Arrenbrech, et al., Osteoporosis International, "Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal woman", Vol. 13, No. 2, pp. 176-183 (2002)
			Black, et al., Journal of Clinical Investigation ., "Raloxifene (LY139481 HCl) Prevents Bone Loss and Reduces Serum Cholesterol Without Causing Uterine Hypertrophy in Ovariectomized Rats", Vol. 93, pp.63-69, (1994)
			Capony et al., Molecular Cell Endocrinology, "In Vivo effect of anti-estrogens on the localization and replenishment of estrogen receptor", Vol. 3, pp. 233, (1975)
			Clark, et al., Steroids, "Estrogen receptor anti-estrogen complex: Atypical binding by uterine nuclei and effects on uterine growth", Vol. 22 (5), pp. 707-718 (1973)
			Delmas, et al., New England Journal of Medicine, "Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentration, and Uterine Endometrium in Postmenopausal Women", Vol. 337, pp.1641-1647, (1997)
			Gauthier et al., Journal of Medicinal Chemistry, "(S)-(+)-4-[7-(2,2-Dimethyl-1-oxopro- poxy)-4-methyl-2-[4-[2-(1-piperidinyl)- ethoxy]phenyl]-2H-1-benzopyran-3-yl]- phenyl 2,2-Dimethylpropanoate (EM-800): A Highly Potent, Specific, and Orally Active Nonsteroidal Antiestrogen", Vol. 40, pp. 2117-2122 (1997)
			Hansson et al., Journal of Pharm. Sci., "Perforated Coated Tablets for Controlled Release of Drugs at a Constant Rate", Vol. 77, pp. 322-324, (1988)
			Osteoporosis Conference Scrip No. 1812-13, Apr. 16-20, pp. 29-31, (1993)
			Shen et al., Journal of Clinical Investigation, "Effects of Reciprocal Treatment with Estrogen and Estrogen plus Parathyroid Hormone on Bone Structure and Strength in Ovariectomized Rats", Vol. 96, pp. 2331-2338, (1995)
			Siris, et al., JAMA 2001, "Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women", Vol. 286(22), pp. 2815-2822 (2001)
			Tang et al., Journal of Bone Mineral Research, "Restoring and Maintaining Bone in Osteogenic Female Rat Skeleton: I. Changes in Bone Mass and Structure", Vol. 7 (9), pp.1093-1104, (1992)
			Willson et al., Journal of Medicinal Chemistry, "3-[4-(1,2-Diphenylbut-1-enyl) phenyl] acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats", Vol. 37, pp.1550-1552, (1994)
			World Health Organization, "Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis, Report of a World Health Organization Study Group. World Health Organization Technical Series 843", (1994)

INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*	ATTY. DOCKET NO. PC23170A	SERIAL NO. 10/596,504
	APPLICANT Hua Zhu Ke	
	FILING DATE	GROUP

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820 **INFORMATION DISCLOSURE**